loading
Precedente Chiudi:
$0.32
Aprire:
$0.3108
Volume 24 ore:
3.78M
Relative Volume:
3.97
Capitalizzazione di mercato:
$9.25M
Reddito:
-
Utile/perdita netta:
$-16.26M
Rapporto P/E:
-0.2622
EPS:
-1.1814
Flusso di cassa netto:
$-13.50M
1 W Prestazione:
+4.04%
1M Prestazione:
-34.75%
6M Prestazione:
-82.96%
1 anno Prestazione:
-93.67%
Intervallo 1D:
Value
$0.3024
$0.348
Intervallo di 1 settimana:
Value
$0.2602
$0.35
Portata 52W:
Value
$0.2602
$5.10

Intensity Therapeutics Inc Stock (INTS) Company Profile

Name
Nome
Intensity Therapeutics Inc
Name
Telefono
203-221-7381
Name
Indirizzo
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Name
Dipendente
16
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
INTS's Discussions on Twitter

Confronta INTS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
INTS
Intensity Therapeutics Inc
0.3101 9.25M 0 -16.26M -13.50M -1.1814
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.73 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.21 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.90 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
546.51 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.84 28.51B 3.81B -644.79M -669.77M -6.24

Intensity Therapeutics Inc Borsa (INTS) Ultime notizie

pulisher
Jun 17, 2025

Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds - The Globe and Mail

Jun 17, 2025
pulisher
Jun 13, 2025

Why Is Intensity Therapeutics Stock (INTS) Down 50% Today? - The Globe and Mail

Jun 13, 2025
pulisher
Jun 13, 2025

Intensity Therapeutics Completes $1.9 Million Stock Offering - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Intensity Therapeutics Stock Falls 44% Today Should You Buy the Dip or Stay Away - thekhabrilal

Jun 13, 2025
pulisher
Jun 12, 2025

Intensify Therapeutics slumps 27%, prices $2M stock offering - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - mx.advfn.com

Jun 12, 2025
pulisher
Jun 12, 2025

Intensity Therapeutics (INTS) Shares Dive 27% Following Public O - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Intensity Therapeutics shares plummet on proposed public offering - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

ThinkEquity Leads Offering for INTS | INTS Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics Prices Public Offering Of 6,675,000 Shares At $0.30 Per Share - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics, Inc. Announces Pricing of Public Offering - The Victoria Advocate

Jun 11, 2025
pulisher
Jun 11, 2025

INTS: Intensity Therapeutics Reports Promising Results from Phas - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics announces public offering of common stock By Investing.com - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics (INTS) Announces Public Offering to Support Clinical Studies | INTS Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics announces common stock offering, no amount given - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics announces public offering of common stock - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - StreetInsider

Jun 11, 2025
pulisher
Jun 11, 2025

SEC Form 424B5 filed by Intensity Therapeutics Inc. - Quantisnow

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics Inc (INTS) Stock: A Year of Stock Market Dynamics - investchronicle.com

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCI - StreetInsider

Jun 11, 2025
pulisher
Jun 11, 2025

Korn Ferry Sets Fiscal Year-End Earnings Release Date: Key Q4 Results Coming June 18 - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity’s cancer drug shows tumor necrosis in early-stage study By Investing.com - Investing.com Nigeria

Jun 11, 2025
pulisher
Jun 11, 2025

DXC Achieves Clean Sweep in NelsonHall's 2025 AI Infrastructure Management Rankings - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics reports data from Invincible-4 study - TipRanks

Jun 11, 2025
pulisher
Jun 09, 2025

Shelton-based biotech faces delisting threat from Nasdaq - Hartford Business Journal

Jun 09, 2025
pulisher
Jun 06, 2025

Intensity Therapeutics Faces Nasdaq Delisting Notice - TipRanks

Jun 06, 2025
pulisher
Jun 05, 2025

ibex to Showcase Industry’s Best AI-Powered CX Solutions at CCW Customer Contact Week 2025 - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

New Cancer Drug Triples Survival Time for Hard-to-Treat Lung Cancer Patients in Phase 2 Trial - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Magnite Revolutionizes CTV Advertising with Exclusive AI Technology for Scene-by-Scene Ad Targeting - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

Full Stock Market News from 2025-06-05 - Stock Titan

Jun 04, 2025
pulisher
Jun 04, 2025

Cognizant Achieves 80% Migration Automation as Snowflake Names it Top Global Implementation Partner - Stock Titan

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics Achieves First Patient Dosing in Friedreich Ataxia Trial, Faces FDA Hurdle - Stock Titan

Jun 04, 2025
pulisher
Jun 04, 2025

AECOM Sets July Payment Date for $0.26 Quarterly DividendKey Dates Inside - Stock Titan

Jun 04, 2025
pulisher
Jun 03, 2025

IonQ Expands Quantum Computing Empire: 20+ Patents Added in Strategic Lightsynq Acquisition - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference - The Globe and Mail

Jun 03, 2025
pulisher
Jun 02, 2025

Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews

Jun 02, 2025
pulisher
Jun 02, 2025

Harte Hanks Acquires Exclusive Rights to License ADS Data Direct's Premier Medical Ailment Database - Stock Titan

Jun 02, 2025
pulisher
May 29, 2025

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - GuruFocus

May 29, 2025
pulisher
May 28, 2025

Intratumoral Cancer Treatment Market 2034: EMA, PDMA, FDA - openPR.com

May 28, 2025
pulisher
May 28, 2025

Intensity Therapeutics to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon - Morningstar

May 28, 2025
pulisher
May 27, 2025

Liposarcoma Clinical Trial Analysis: Key Insights into Rich - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Clean Tech Breakthrough: Zentek Partners With RSK to Launch Advanced Air Filters Across 20+ Global Markets - Stock Titan

May 27, 2025
pulisher
May 23, 2025

Imunon Stock Price, Quotes and Forecasts | NASDAQ:IMNN - Benzinga

May 23, 2025
pulisher
May 23, 2025

Intensity Therapeutics stock hits 52-week low at $0.29 By Investing.com - Investing.com Nigeria

May 23, 2025
pulisher
May 23, 2025

Intensity Therapeutics stock hits 52-week low at $0.29 - Investing.com

May 23, 2025
pulisher
May 22, 2025

Alliance Global Partners Adjusts Price Target for Intensity Therapeutics (INTS) | INTS Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Assembly's New META-Backed Marketing Tool Cuts Modeling Time 26%, Boosts ROI 13% With AI Innovation - Stock Titan

May 22, 2025
pulisher
May 21, 2025

Benchmark maintains Speculative Buy on Intensity Therapeutics stock - Investing.com

May 21, 2025
pulisher
May 21, 2025

Benchmark maintains Speculative Buy on Intensity Therapeutics stock By Investing.com - Investing.com India

May 21, 2025
pulisher
May 20, 2025

Intensity Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks

May 20, 2025

Intensity Therapeutics Inc Azioni (INTS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.55
price up icon 0.28%
$35.85
price down icon 0.08%
$21.01
price up icon 2.04%
$100.42
price up icon 0.85%
$106.39
price down icon 0.32%
biotechnology ONC
$242.84
price up icon 0.42%
Capitalizzazione:     |  Volume (24 ore):